Source file signed link, expires in 15 minutes
Extracted text 15
Page 1
Public
Expose
Company Presentation
PT Merck Tbk
8 October 2026
As part of its commitment to information transparency and good
corporate governance, PT Merck Tbk presents the Company's latest
developments, covering operational and business progress as well as
its future focus and strategy.
1 Public Expose PT Merck Tbk 2026
Page 2
List of Content
01 About Merck …………………………………..3
Company Update
02 1. Impairment Booking …………….………..4
2. Performance …………………………..……..8
3. Moving Forward …..…..…..…….….. 11
03 Summary ………………..……………….14
2 Public Expose PT Merck Tbk 2026
Page 3
About
As a science and technology company, nothing small in what we do.
Our passion for science and technology drives our approximately 63,000
Merck
employees in 65 countries to find solutions to some of today's toughest
challenges and create a more sustainable way of life.
PT Merck Tbk MANAGEMENT Our Plant is responsible for product
development, manufacturing, logistics and
• Koji Okamoto
Founded in 1970, PT Merck Tbk became a President Commissioner
warehousing, quality control of pharmaceutical
public company in 1981, and was one of drugs, and packaging of medical devices.
• Agus Prabowo
the first companies listed on the Independent Commisioner • Total site area: 21,760 m²
Indonesia Stock Exchange. • Built-on area: 5,539 m²
• Manufacturing + Packaging: +1,920 m²
BOARD OF DIRECTORS • Warehouse: 2,500 PP
• Capacity: 769 million tablets & capsules
• Evie Yulin
OUR PROFILE President Director PT Merck Tbk
• Arryo Aritrixso Teguh Putranto CORE AREAS OF EXPERTISE
364 Employees
Wachjuwidajat • Production of oral solid (sugar and film-coated
Director PT Merck Tbk tablets, gelatin capsules)
2 million Healthcare Patients • Production of oral nonsterile liquids, nasal drops
• Bambang Nurcahyo
Director PT Merck Tbk and spray
1.6 Billion Tablet and Capsule • Handling cold-chain products (Biotech)
Capacity in Factory
MARKET
Expertise in thyroid, diabetes & SUSTAINABILITY
• Local – 56%
prediabetes, cardiovascular, growth For us, scientific progress and responsible • Export – 44%
hormone, fertility, multiple sclerosis, business practices must go hand in hand.
and cancer
Click to learn about our sustainability goals
3 Public Expose PT Merck Tbk 2026
Page 4
Impairment
Booking
Information Disclosure Sep 24, 2026
4 Public Expose PT Merck Tbk 2026
Page 5
BACKGROUND
From capacity investment to changes in
utilization
The Journey of the Pasar Rebo Factory Since 2015
Capacity expansion investment targeting an output of two billion tablets: major facility
2015–2018 renovation and the purchase of new machinery. Renovation remains necessary to meet GMP
requirements.
2018 Merck Group divested its Consumer Health business, which significantly impacted
production capacity utilization and utility facilities at the Jakarta site.
2026–2027 The Manufacturing Service Agreement with P&G is entering its final period; volume and cash
flow outlooks are changing materially.
4
5 Public Expose PT Merck Tbk 2026
Page 6
Why is the impairment booked now
Outlook for material changes in volume, utilization, and cash flow prospects.
The booking of an asset impairment of IDR 87 billion complies with PSAK and
Merck Group accounting policies and reflects the fair and transparent value of
the assets.
The Manufacturing Service Agreement with P&G was most recently signed on September 1,
Contract 2026, and expires on December 31, 2027.
Volume P&G products account for approximately 80% of the factory's current production volume.
Accounting Booking is carried out in accordance with applicable PSAK provisions.
Booked in September 2026 so that it is reflected in the Q3 2026 accounts and disclosed to the
Transparency public sooner.
This valuation adjustment risk has been disclosed in the 2024 and 2025 Annual Reports.
6 Public Expose PT Merck Tbk 2026
Page 7
Company
Performance
7 Public Expose PT Merck Tbk 2026
Page 8
COMPANY PERFORMANCE
The financial foundation remains sound.
PT Merck Tbk Performance semester I 2026
0,27x 5x
+396%
Year-on-year profit growth, or almost fourfold in
Rasio debt-to-equity
9,10%
Rasio lancar
11,59%
the first semester of 2026. Return on assets Return on equity
This positive performance does not eliminate the need to recognize asset impairment at the Pasar
Rebo site. The expiration of the P&G contract will impact the Company's revenue.
6
8 Public Expose PT Merck Tbk 2026
Page 9
MARKET POSITION
Maintained market leadership
All of Merck's key therapeutic areas are ranked #1*
Thyroid Cardiovaskular Diabetes Multiple sclerosis
Euthyrox, Thyrozol Concor Glucophage, Glucovance Mavenclad, Rebif
Fertility Growth hormone Onkologi
Pergoveris, Gonal-f Saizen Erbitux (colorectal cancer)
7,7% 6,5% 6,2% #8
Merck growth Ethical market Total market Pharma MNC ranking
Strengthened by Public-Private Partnerships
Focusing on thyroid, endocrinology, and fertility to provide capacity-building education for healthcare professionals,
as well as education for the public regarding diseases and the importance of early detection.
*Market Data (IQVIA 2Q2026; IPMG YTD June 2026; Market Insight)
9 Public Expose PT Merck Tbk 2026
Page 10
Moving
Forward
10 Public Expose PT Merck Tbk 2026
Page 11
MOVING FORWARD
New Medicines
Acceleration Launching Plan
(in progress) SpringWorks
Acquisition by
Merck KGaA
Bavencio drugs (1 Juli 2025)
for bladder cancer,
kidney cancer TEPMETKO Adds rare tumor product
(launched 2024) (lung cancer drug) portfolio
and Mavenclad –
multiple sclerosis Marketing in Indonesia
drug (launch 2023) management’s awaiting
penetrate well. business case.
11 Public Expose PT Merck Tbk 2026
Page 12
MOVING FORWARD
The Company's focus after contract expiration
Production of prescription drugs, importation of biotechnology products, and export expansion.
Pasar Rebo Production Biotechnology Portfolio Export expansion
Imports of finished biotechnology Glucophage XR, Glucophage IR,
The factory continues to produce
products account for approx. 60% Glucovance, and Concor are
Merck prescription medicines for
of Healthcare sales, while in-house gradually entering other Asian
domestic and export markets.
production accounts for around markets.
40%.
Export expansion timeline
2026 2027–2029 Hong Kong, Singapura &
The Philippines (Glucovance)
Brunei, Malaysia, Thailand
7
12 Public Expose PT Merck Tbk 2026
Page 13
SUMMARY 13 Public Expose PT Merck Tbk 2026
Page 14
IN A NUTSHELL
A single accounting decision,
a business direction that remains clear.
• The IDR 87 billion impairment charge reflects the fair and transparent value of the
assets.
• The calculation is based on independent valuations and applicable accounting guidelines.
• The Pasar Rebo Plant continues to manufacture prescription medicines, supported by
expanded exports to Asia.
• The Company’s financial foundation is solid, and Merck maintains a leading market
position
14 Public Expose PT Merck Tbk 2026
Page 15
Kontak
Kantor Pusat & Pabrik
JL. TB Simatupang No. 8, Pasar Rebo
Jakarta Timur
Kantor Healthcare & Life Science
Perkantoran Hijau Arkadia
G Tower 9th Floor
Jl. TB Simatupang Kav. 88 Pasar Minggu
Jakarta Selatan
www.merck.co.id Dedicated to Human Progress
PHONE +62 21 2856 5600
FAX +62 21 2856 5601
Email contact.id@merckgroup.com
Merck Indonesia MerckIndonesia
MerckIndonesia Merckgroup
MerckIndonesia Merck Indonesia
15 Public Expose PT Merck Tbk 2026
Names mentioned 0 people and organisations named in the text · linked when the evidence is strong
The name pass has not read this document yet.
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.